Expanded Access Policy

Biosyngen Pte. Ltd. is an Immuno-Oncology company committed to developing and bringing new and innovative immunotherapeutic products to patients, such as BRG01 and BST02. The company has obtained approval from the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) to begin clinical trials.

In future, participation in one of our clinical trials is the most appropriate way to access our investigational medical products. Expanded access, also commonly known as “compassionate use”, is a potential pathway for patients with serious or life-threatening diseases to explore investigative medical products for treatment – due to no existing or limitations of treatments approved by regulators.

We understand patients may have an interest in accessing our immune-oncology products prior to regulatory approval. At present, Biosyngen Pte. Ltd. has yet to offer an expanded access program (including BRG01 and BST02). To learn more about our clinical trials, please visit our website at:  or contact us at: for more information.